Back

Safety and efficacy of edoxaban monotherapy vs dual antithrombotic therapy in patients with stable coronary artery disease and non-valvular atrial fibrillation: a systematic review and meta-analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in coronary artery disease (2) Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Paolo Miguel Go

Saint Lukes Medical Center Global City, Taguig (Philippines)

6 More presentations in this session

Presentation thumbnail
Combination therapy rapidly improves symptoms and quality of life in recently diagnosed angina patients: the COMBINE Angina study
Professor M. Marzilli (Pisa, IT)
Abstract Slides
Presentation thumbnail
Efficacy and safety of selective serotonin reuptake inhibitors on cardiovascular outcomes of patients with post-acute coronary syndrome depression: a systematic review and meta-analysis
Doctor J. Magno (Angeles City, PH)
Abstract Slides
Presentation thumbnail
Efficacy of PCSK9 inhibitors combined with statins versus statin monotherapy for secondary cardiovascular prevention: a systematic review and meta-analysis
Mr M. Lang (Pilar, AR)
Abstract Slides Video
Presentation thumbnail
Colchicine in acute coronary syndromes: a meta-analysis of 12.602 patients
Associate Professor G. Liuzzo (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Association of colchicine with atrial fibrillation and safety outcomes in patients with acute coronary syndrome
Doctor M. Tao (Hartford, US)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy in coronary artery disease (2)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin
thumbnail
Congress Presentation
Safety and efficacy of prolonged antithrombotic therapy in high-risk patients followed in a dedicated secondary prevention consultation
thumbnail
Congress Presentation
Navigating optimal antithrombotic therapy in atrial fibrillation patients with PCI: insights from the EPIC-CAD trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources